EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies

Vincenzo Trapanese iD, Annamaria Dagostino iD, Maria Resilde Natale iD, Federica Giofrè, Clara Vatalaro iD, Melania Melina, Francesca Cosentino, Silvia Sergi, Felice Imoletti, Rocco Spagnuolo iD, Franco Arturi

Life · 23.05.2025 · 15 (6) · 843

DOI: 10.3390/life15060843 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 23.05.2025. Verfasst von Vincenzo Trapanese und 10 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Unit, Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Obesity, insulin resistance, type 2 diabetes mellitus (T2DM) and metabolic syndrome have been largely correlated to a reduction in bacterial load and diversity, resulting in a condition known as intestinal dysbiosis. The recent emergence of novel antidiabetic medications has been demonstrated to exert a favourable influence on the composition of the intestinal microbiota. Incretin-based therapy exerts a multifaceted influence on the composition of the gut microbiota, leading to alterations in bacterial flora. Of particular significance is the capacity of numerous metabolites produced by the gut microbiota to modulate the activity and hormonal secretion of enteroendocrine cells. This review examines the effects of dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/gastric inhibitory polypeptide (GIP) receptor dual agonists on the composition of the gut microbiota in both mice and human subjects. The nature of this interaction is complex and bidirectional. The present study demonstrates the involvement of the incretinic axis in modulating the microbial composition, with the objective of providing novel preventative strategies and potential personalised therapeutic targets for obesity and T2DM.

Schlagwörter

Stichwörter der Autor:innen

DPP-4 inhibitorGLP-1 receptor agonistGLP-1/GIP receptor dual agonistgut microbiotaincretinobesitytype 2 diabetes mellitus

Autor:innen und Institutionen

  • Internal Medicine Unit, Department of Medical and Surgical Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
  • Department of Health Sciences, "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.
  • Research Centre for the Prevention and Treatment of Metabolic Diseases (CR METDIS), "Magna Graecia" University of Catanzaro, 88100 Catanzaro, Italy.

ORCID-Profile: Vincenzo Trapanese, Annamaria Dagostino, Maria Resilde Natale, Clara Vatalaro, Rocco Spagnuolo

Zitieren

APA

Trapanese, V., Dagostino, A., Natale, M. R., Giofrè, F., Vatalaro, C., Melina, M., Cosentino, F., Sergi, S., Imoletti, F., Spagnuolo, R., & Arturi, F. (2025). Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies. Life, 15(6), 843. https://doi.org/10.3390/life15060843

Vancouver

Trapanese V, Dagostino A, Natale MR, Giofrè F, Vatalaro C, Melina M, et al. Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies. Life. 2025;15(6):843. doi:10.3390/life15060843

BibTeX
@article{Trapanese2025,
  author = {Trapanese, Vincenzo and Dagostino, Annamaria and Natale, Maria Resilde and Giofrè, Federica and Vatalaro, Clara and Melina, Melania and Cosentino, Francesca and Sergi, Silvia and Imoletti, Felice and Spagnuolo, Rocco and Arturi, Franco},
  title = {Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies},
  journal = {Life},
  year = {2025},
  volume = {15},
  number = {6},
  pages = {843},
  doi = {10.3390/life15060843}
}
Kostenlos starten →